A multi-center, randomized, double-blind, parallel-group, placebo-controlled study of mepolizumab 100 mg SC as add-on treatment in participants with COPD experiencing frequent exacerbations and characterized by eosinophil levels (Study 208657)

Project: Research

Project Details

StatusActive
Effective start/end date9/01/20 → 8/01/25

Keywords

  • clinical trial
  • treatment safety
  • treatment efficacy
  • chronic obstructive pulmonary disease (COPD)